Loading…
Clinical-stage biotech developing antibody treatments for thyroid eye disease, competing with Amgen's Tepezza.
Clinical-stage biotech developing antibody treatments for thyroid eye disease, competing with Amgen's Tepezza.
No approved product yet, so it earns no sales and is funded by raising capital from investors. The value rests on two antibody drugs aimed at the same cell receptor, IGF-1R, that Tepezza targets, one given by intravenous infusion and one by injection under the skin.
Moat: none (IP / patents). Pre-commercial; must differentiate on dosing convenience versus Amgen's approved Tepezza.
Headquarters: Waltham, Massachusetts, US · Founded: 2020 · Employees: 252
Size Viridian Therapeutics (VRDN) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $3.23B, the 1495th largest of 3,117 United States companies the cockpit tracks. Shares closed at $28.49 on 6 Nov 2026.
Performance Over six months the shares gained 71.5%, against -3.7% for the median peer and -1.1% for the United States market (cap-weighted) — highest of 20 in its peer set.
Growth Revenue fell 62.8% over the last twelve months (peer median +18.6%); the operating margin is -1,781.4% (peer median 15.3%).
Valuation It trades at 99.3× enterprise value to sales against a peer median of 4.2× (most expensive of 19).
Credit Viridian Therapeutics has 1 bond outstanding ($250M).
Next results Next results expected around 11 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $26.3M | $70.8M | $302,000 | $314,000 | $1.77M |
| Revenue growth | — | +23,360% | -4% | -82% | — |
| Gross profit | $23.9M | $69.7M | -$938,000 | -$1.01M | $1.02M |
| EBITDA | -$468M | -$362M | -$298M | -$253M | -$134M |
| Net income | -$435M | -$282M | -$209M | -$238M | -$130M |
| Free cash flow | -$344M | -$277M | -$233M | -$185M | -$94.6M |
| Capital expenditure | $1.94M | $495,000 | $511,000 | $898,000 | $797,000 |
| Total debt | $243M | $50.7M | $23.1M | $22.0M | $6.36M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Viridian Therapeutics VRDN | $3.23B | +72% | -63% | -1,781% | 99.3× | n/a |
| Amgen AMGN | $249B | +40% | +9% | 36% | 7.4× | 1.8% |
| Immunovant IMVT | $6.31B | +5% | n/a | n/a | n/a | n/a |
| argenx SE Sponsored ADR ARGX | $57.5B | +19% | +71% | 29% | 10.0× | 10.9% |
| Roche RO.SW | $385B | +22% | -1% | 31% | 5.6× | 0.9% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | VRDN | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +55.3% | +0.6% | highest of 21 |
| 6-month return | +71.5% | -3.7% | highest of 20 |
| Distance from 52-week high | -16.9% | -25.8% | 7th highest of 21 |
| Revenue growth (TTM) | -62.8% | +18.6% | 2nd lowest of 19 |
| Operating margin | -1,781.4% | 15.3% | lowest of 19 |
| EV / Sales | 99.3× | 4.2× | most expensive of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Viridian Therapeutics VRDN | United States | $3.23B | +72% | -63% | -1,781% | 99.3× | n/a | n/a |
| Arcutis Biotherapeutics ARQT | United States | $3.21B | +21% | +76% | 7% | 6.7× | 48.9% | +367.3% |
| Tasly Pharmaceutical 600535.SS | China | $3.20B | -5% | -4% | 19% | 2.3× | -7.6% | -9.6% |
| Chengdu Kanghong Pharmaceutical 002773.SZ | China | $3.18B | -7% | -11% | 24% | 3.6× | -2.2% | +7.0% |
| Acutaas Chemicals ACUTAAS.NS | India | $3.28B | +39% | +45% | 36% | 19.3× | n/a | n/a |
| China Medical System 0867.HK | Hong Kong | $3.30B | -16% | +15% | 20% | 2.1× | 2.9% | +2.7% |
| China National Medicines 600511.SS | China | $3.31B | +2% | +3% | 4% | 0.3× | -9.8% | +5.4% |
| Wockhardt WOCKPHARMA.NS | India | $3.35B | +19% | +26% | 13% | 8.9× | 56.9% | +4.2% |
| Piramal Pharma PPLPHARMA.NS | India | $3.37B | +30% | +9% | 3% | 3.8× | n/a | n/a |
| Tarsus Pharmaceuticals TARS | United States | $3.38B | +12% | +86% | -10% | 4.6× | 31.9% | +159.5% |
| Hybio Pharmaceutical 300199.SZ | China | $3.08B | +16% | +70% | 31% | 14.7× | 40.1% | +6.1% |
| Shanghai Henlius Biotech 2696.HK | Hong Kong | $3.41B | -37% | +33% | 12% | 3.7× | 15.2% | +61.4% |
| Viking Therapeutics VKTX | United States | $3.42B | -17% | n/a | n/a | n/a | n/a | n/a |
| IDEAYA Biosciences IDYA | United States | $3.02B | +10% | -83% | -1,267% | 60.5× | n/a | n/a |
| Betta Pharmaceuticals 300558.SZ | China | $3.01B | -9% | +16% | 11% | 5.8× | 25.2% | +14.0% |
| Jiangsu Nhwa Pharmaceutical 002262.SZ | China | $3.47B | +2% | +3% | 19% | 3.1× | -2.2% | +12.0% |
| Parabilis Medicines PBLS | United States | $3.52B | n/a | n/a | n/a | n/a | n/a | n/a |
| Sam Chun Dang Pharm 000250.KS | South Korea | $2.91B | -59% | +21% | 7% | 15.4× | n/a | n/a |
| Suzhou Zelgen Biopharmaceuticals 688266.SS | China | $3.60B | -13% | +136% | 29% | 12.8× | 20.5% | +98.4% |
| Simcere Pharmaceutical 2096.HK | Hong Kong | $3.63B | -7% | +27% | 18% | 2.7× | -2.8% | +10.6% |
| Joincare Pharmaceutical Group Industry 600380.SS | China | $2.86B | -4% | -12% | 18% | 1.6× | -13.1% | +2.4% |
Viridian Therapeutics has 1 bond outstanding with $250M face value.